Products

LungQ 4
Thirona BV
Oncology AI
Thirona's LungQ 4 is an AI-powered CT analysis software that provides comprehensive quantitative insights for thoracic CT images, enhancing precision in pulmonary care and supporting diagnosis, treatment planning, and follow-up examinations for various lung diseases.
LungQ
Thirona BV
Radiology & Imaging AI
LungQ by Thirona offers AI-powered analysis of thoracic CT scans for specialized clinical care and interventional pulmonology, providing quantitative support for diagnosis, treatment planning, and follow-up examinations of lung diseases.

See all 2 products →

About Thirona BV

Thirona BV is a leading healthcare AI company specializing in advanced analysis of medical lung images to drive precision medicine. The company develops cutting-edge, clinically proven AI software, such as LungQ™, which is utilized by clinicians in hundreds of hospitals globally. Their solutions go beyond improving routine efficiency, aiming to unlock new treatment possibilities for both common and rare pulmonary conditions that conventional methods often cannot address.

For physicians, Thirona’s AI technology offers high-precision quantitative analysis of thoracic CT scans, aiding in the detection, evaluation, and treatment planning of various lung diseases. This includes detailed quantifications of anatomical volumes, disease distributions, airway and vascular morphology, and fissure completeness. The company’s platforms are instrumental in accelerating imaging-based exploratory research studies and large multi-site clinical trials for novel pharmaceutical drug development, ultimately supporting personalized treatment strategies and enhancing the precision and efficiency of bronchoscopic and surgical lung interventions.

Thirona’s mission, spearheaded by founder and CEO Dr. Eva van Rikxoort, is to make personalized lung care widely accessible, ensuring every patient receives optimal and timely treatment regardless of disease complexity. They collaborate closely with leading research institutes, academic hospitals, pharmaceutical innovators, and MedTech partners to advance precision medicine for lung diseases.

Focus Areas

AI-powered medical image analysis lung diseases thoracic CT scans precision medicine drug development pulmonary interventions COPD asthma lung cancer cystic fibrosis idiopathic pulmonary fibrosis

Business Intelligence

Key InvestorsHERAN Partners, Borski Fund, European Innovation Council (EIC)
PartnershipsBlackford, VIDA Diagnostics, Voiant
AcquisitionsAcquired by Revenio Group (Aug 20, 2024); spun out Retina division into Thirona Retina BV (Jan 1, 2023)
TechnologyAI-powered advanced segmentation and quantification capabilities for high-precision assessment of lung structures and disease, deep learning models, modular LungQ® technology, clinically-relevant use cases, robust algorithms
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Specialized Disease Focus
Thirona BV specializes in AI-powered medical image analysis for a wide range of lung diseases, including COPD, asthma, lung cancer, cystic fibrosis (CF), idiopathic pulmonary fibrosis (ILD), and bronchiectasis. Their solutions are designed to provide precise insights into these complex conditions.
AI-Powered Image Analysis
Their core offering, the LungQu00ae platform, leverages advanced AI and deep learning for robust segmentation and precise quantification of bronchial, parenchymal, and vascular lung structures from thoracic CT scans. This enables automated, accurate assessments across various pulmonary diseases.
Precision Medicine & Drug Development
Thirona's technology supports precision medicine by enabling detailed phenotyping of respiratory diseases, which is crucial for refining patient populations in clinical trials and accelerating drug development. Their quantitative CT (QCT) analysis provides objective evidence for treatment effects.
Pulmonary Interventions
The LungQu00ae platform aids in advancing minimally invasive pulmonary interventions by providing enhanced anatomical understanding, supporting precise access planning for distal airway targets in procedures for lung cancer, emphysema, and chronic airway diseases.
Key Differentiator: Validation & Reproducibility
Thirona's LungQu00ae portfolio is extensively validated in over 200 peer-reviewed publications, ensuring reliable and reproducible results across diverse patient populations and disease severities. This scientific rigor underpins the clinical utility of their AI solutions.
Key Differentiator: Early Detection & Quantification
The technology excels at sensitive detection of early and subtle structural and functional changes in the lung, often exceeding traditional visual and expert-driven methods. It provides objective quantification of abnormalities like emphysema, trapped air, bronchiectasis, and mucus impaction.
Technology Stack: LungQu00ae Platform
The LungQu00ae platform is a modular AI technology built on advanced segmentation and quantification capabilities. It offers a wide portfolio of measurements and analytical capabilities tailored to clinically relevant use cases, backed by robust algorithm engineering.
Technology Stack: Deep Learning & QCT
Their solutions incorporate state-of-the-art deep learning technology for high-precision assessment of lung structures and disease. This includes advanced QCT analysis for comprehensive structural profiling of the lung, including airways, blood vessels, and parenchyma.
Physician Tip

For physicians, Thirona's AI-powered LungQu00ae software offers automated, accurate, and reproducible quantitative analysis of thoracic CT scans, significantly reducing the time and expertise traditionally required for detailed assessments, especially in complex conditions like Cystic Fibrosis (e.g., PRAGMA-AI). This enables earlier detection of subtle disease progression, more precise patient phenotyping, and objective monitoring of treatment response, leading to more personalized and timely patient care. The enhanced anatomical understanding also supports better planning and guidance for pulmonary interventions.

Thirona's LungQu00ae platform is designed for seamless integration, often through AI marketplaces or distribution platforms like Blackford Analysis and VIDA Intelligence Platform. It can also be deployed as a standalone web-based solution or locally on dedicated hardware. The output includes HTML reports, PDF reports, JSON files, segmentation overlays, and quantitative values, facilitating integration into existing clinical workflows and research initiatives.

Products by Thirona BV

2 products in the directory

LungQ 4
Thirona BV
Oncology AI
Thirona's LungQ 4 is an AI-powered CT analysis software that provides comprehensive quantitative insights for thoracic CT images, enhancing precision in pulmonary care and supporting diagnosis, treatment planning, and follow-up examinations for various lung diseases.
LungQ
Thirona BV
Radiology & Imaging AI
LungQ by Thirona offers AI-powered analysis of thoracic CT scans for specialized clinical care and interventional pulmonology, providing quantitative support for diagnosis, treatment planning, and follow-up examinations of lung diseases.

What the Web Says

Thirona BV is a Dutch company specializing in AI-based automated analysis tools for medical images, particularly chest CT scans. They have received significant funding for their AI-based lung platform, which aims to accelerate early lung cancer detection and aid in the diagnosis of pulmonary hypertension. Their products, like LungQ, focus on high-precision quantitative analysis for clinical applications.

Overall: Positive

Strengths

  • AI-powered for high-precision analysis of lung structures and diseases
  • Accelerates early lung cancer detection
  • Aids in early diagnosis of pulmonary hypertension and vascular diseases
  • Intuitive for users and medical specialists
  • Strong focus on bridging academic theory and clinical application
  • Modular technology adaptable to various clinical use cases

Limitations

  • No specific product or employer reviews found on G2, Glassdoor, Capterra, or Reddit.
  • Limited information available regarding company culture or employee experiences from public review sites.

Based on reviews from: BioWorld, Thirona Official Website

Last updated: 2026-07-19

Videos

News, demos, and interviews about Thirona BV.

Loading videos...

Videos load interactively. If none appear, search YouTube for Thirona BV →

View all on YouTube

Press & Coverage

Thirona
Thirona Receives FDA Clearance for LungQu00ae 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market
Thirona announced FDA 510(k) clearance for LungQu00ae 4, its AI-powered CT analysis software, which offers enhanced peripheral airway segmentation, estimated chronic perfusion defects from CT, and improved post-treatment detection of endobronchial implants. This clearance builds on version 3 and aims to advance precision pulmonary care.
2025-10
Thirona
Thirona Announces Partnerships to Enhance AI-based Lung Image Analysis
Following FDA approval for LungQ (v3.0.0) in January 2024, Thirona announced multiple partnerships with research institutions and medical companies to advance precision medicine for pulmonary diseases. These collaborations aim to integrate Thirona's AI-based lung analysis solutions into clinical workflows and support imaging-based clinical trials.
2024-06
Thirona
Thirona Spinout Thirona Retina BV Acquired by Revenio Group
Thirona announced the divestment of its retina division, Thirona Retina BV, to Revenio Group Corporation's subsidiary Icare Finland Oy. This move allows Thirona to focus on its long-term growth strategy in AI-driven lung imaging for pulmonary precision medicine.
2024-08
Thirona
Voiant and Thirona announce commercial partnership for full scope services in imaging-based clinical trials for pulmonary diseases.
Voiant and Thirona have formed a global commercial partnership to provide comprehensive services for clinical trials involving AI-powered lung image analysis. This collaboration combines Voiant's expertise in clinical trial support with Thirona's advanced lung image analysis capabilities.
2024-04
Silicon Canals
Dutch AI-powered medtech Thirona raises u20ac7.5M to drive precision medicine innovations
Nijmegen-based Thirona secured u20ac7.5 million in funding, including a u20ac5 million investment from HERAN Partners and Borski Fund, and a u20ac2.5 million grant from the European Innovation Council (EIC). This funding will accelerate the adoption of its AI-powered innovations for precision medicine in lung diseases.
2024-03
Thirona
Thirona Raises u20ac7.5 Million New Financing
Thirona announced the successful completion of a new investment round, securing u20ac7.5 million in financing from HERAN Partners, Borski Fund, and a grant from the European Innovation Council (EIC). This funding will be used to accelerate the adoption of its AI-powered innovations for precision medicine in lung diseases.
2023-09
BioWorld
Thirona secures $2.73M in funding from EIC for AI-based lung platform
Thirona BV was awarded $2.73 million from the European Innovation Council (EIC) to expedite the development of its AI-based lung platform for analyzing chest CT imaging. This grant is part of the EIC accelerator program, aiming to scale up breakthrough innovators.
2023-07
Eye Care Network
Thirona spins out retina business to pursue long-term growth plans
Thirona announced its plan to spin out its retina division into Thirona Retina BV, effective January 1, 2023. This strategic move allows Thirona BV to focus solely on AI-powered solutions for lung diseases, while Thirona Retina BV concentrates on eye diseases.
2023-01

Frequently Asked Questions

Thirona BV's flagship product is LungQ, an AI-powered software designed for the advanced analysis of thoracic CT scans. It provides quantitative measurements to aid in the detection, evaluation, and treatment planning for a wide range of lung diseases, including COPD, asthma, lung cancer, cystic fibrosis, idiopathic pulmonary fibrosis, and bronchiectasis.
Thirona's LungQ platform leverages AI for high-precision segmentation and quantification of lung structures, airways, and vasculature from CT scans. This enables detailed characterization of disease patterns, supporting personalized treatment planning, monitoring disease progression, and providing objective evidence for precision-driven decision-making in pulmonary care.
Thirona BV operates under an ISO 13485 certified Quality Management System and is compliant with the EU Medical Device Regulation (MDR) 2017/745. Their LungQ software has received U.S. Food and Drug Administration (FDA) 510(k) clearance, with the latest version 4 cleared in October 2025, making it available for clinical use in various global markets.
Thirona's LungQ provides accurate, sensitive, and reproducible quantitative CT analysis vital for respiratory clinical trials, supporting patient phenotyping, assessing treatment response, and evaluating drug efficacy. For pulmonary interventions, LungQ acts as a 'map' for lung anatomy, guiding bronchoscopic navigation and surgical interventions to enhance precision and efficiency.
Thirona BV has formed strategic partnerships with companies like Voiant and VIDA Diagnostics to offer comprehensive services for imaging-based clinical trials in pulmonary diseases. They also collaborate with Blackford to integrate LungQ into broader AI platforms, enhancing access for healthcare professionals.
Founded in 2014, Thirona BV spun out its retina division in 2023 to fully concentrate on AI-powered solutions for precision medicine in lung diseases. The company has demonstrated stability through consistent growth, securing Series B funding in September 2023, and expanding its team and advisory board.
Healthcare providers interested in pricing, implementation, or support for Thirona's LungQ solution can contact the company directly through their official website. Thirona offers general inquiry and product information contact options to address specific organizational needs.

Related Companies

Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]

Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]

Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]

Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]

Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]

SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.